



Before



After

**Before and After Photos of Latisse™ Clinical Trial Patient – Individual Results May Vary Following Treatment**

**Before Photo:** Eyelashes of patient at start of clinical trial.

**After Photo:** Increased eyelash prominence of patient at end of 16-week clinical trial.

The U.S. Food and Drug Administration (FDA) has approved Latisse™ (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. Latisse™ is the first and only science-based treatment approved by the FDA to enhance eyelash prominence as measured by increases in length, thickness and darkness of eyelashes.